Literature DB >> 20216376

Development of disseminated histiocytic sarcoma in a patient with autoimmune lymphoproliferative syndrome and associated Rosai-Dorfman disease.

Girish Venkataraman1, Kenneth L McClain, Stefania Pittaluga, V Koneti Rao, Elaine S Jaffe.   

Abstract

Patients with autoimmune lymphoproliferative syndrome (ALPS) have defective lymphocyte apoptosis with increased risk for lymphoid malignancies. Herein, we report a patient with ALPS who developed histiocytic sarcoma in a background of sinus histiocytosis and massive lymphadenopathy or Rosai- Dorfman disease. This patient had documented ALPS type Ia with a germline missense mutation in exon 9 of the TNFRSF6 gene (973 A>T, D244V) encoding Fas (CD95/Apo-1). He presented at 10 months with hepatosplenomegaly and autoimmune hemolytic anemia and was diagnosed with ALPS. At the age of 6 (1/2) years, he developed classic Hodgkin lymphoma which was treated using standard chemotherapy. Two years later, a biopsy of a positron emission tomography-positive axillary node showed features of ALPS and focal involvement by sinus histiocytosis and massive lymphadenopathy. Thereafter, the patient continued to have continued lymphadenopathy and progressive splenomegaly, leading to exploratory surgery at the age of 13 years for suspicion of lymphoma. Para-abdominal nodes revealed sheets of malignant- looking histiocytes with increased mitotic activity and areas of necrosis, indicative of histiocytic sarcoma. Spleen and lymph nodes also showed involvement by Rosai-Dorfman disease. Both components had an identical phenotype of S-100+/CD68+/ CD163+. The occurrence of malignancies involving 2 separate hematopoietic lineages in ALPS has not been reported earlier. Given the central role of defective Fas signaling in ALPS, histiocytes may be yet another lineage at risk for neoplastic transformation secondary to a block in apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20216376      PMCID: PMC2861546          DOI: 10.1097/PAS.0b013e3181d5ddf8

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death.

Authors:  D M Hockenbery; M Zutter; W Hickey; M Nahm; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

2.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.

Authors:  S E Straus; E S Jaffe; J M Puck; J K Dale; K B Elkon; A Rösen-Wolff; A M Peters; M C Sneller; C W Hallahan; J Wang; R E Fischer; C E Jackson; A Y Lin; C Bäumler; E Siegert; A Marx; A K Vaishnaw; T Grodzicky; T A Fleisher; M J Lenardo
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

3.  Sinus histiocytosis with massive lymphadenopathy: evidence for its relationship to macrophages and for a cytokine-related disorder.

Authors:  P Middel; B Hemmerlein; A Fayyazi; U Kaboth; H J Radzun
Journal:  Histopathology       Date:  1999-12       Impact factor: 5.087

4.  Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.

Authors:  G H Fisher; F J Rosenberg; S E Straus; J K Dale; L A Middleton; A Y Lin; W Strober; M J Lenardo; J M Puck
Journal:  Cell       Date:  1995-06-16       Impact factor: 41.582

5.  A novel lymphoproliferative/autoimmune syndrome resembling murine lpr/gld disease.

Authors:  M C Sneller; S E Straus; E S Jaffe; J S Jaffe; T A Fleisher; M Stetler-Stevenson; W Strober
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

6.  Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease).

Authors:  M Paulli; G Bergamaschi; L Tonon; A Viglio; R Rosso; F Facchetti; M L Geerts; U Magrini; M Cazzola
Journal:  Br J Haematol       Date:  1995-10       Impact factor: 6.998

7.  Involvement of the bcl-2 gene in human follicular lymphoma.

Authors:  Y Tsujimoto; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

8.  Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma.

Authors:  Yoshitaka Hosokawa; Hiroko Suzuki; Yasuyuki Suzuki; Ryosuke Takahashi; Masao Seto
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

9.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.

Authors:  F Rieux-Laucat; F Le Deist; C Hivroz; I A Roberts; K M Debatin; A Fischer; J P de Villartay
Journal:  Science       Date:  1995-06-02       Impact factor: 47.728

10.  Membrane-bound Fas ligand only is essential for Fas-induced apoptosis.

Authors:  Lorraine A O' Reilly; Lin Tai; Lily Lee; Elizabeth A Kruse; Stephanie Grabow; W Douglas Fairlie; Nicole M Haynes; David M Tarlinton; Jian-Guo Zhang; Gabrielle T Belz; Mark J Smyth; Philippe Bouillet; Lorraine Robb; Andreas Strasser
Journal:  Nature       Date:  2009-10-01       Impact factor: 49.962

View more
  13 in total

1.  Histiocytic sarcoma with two immunohistopathologically distinct populations.

Authors:  Kanako Wakahashi; Manabu Shimoyama; Yoshio Katayama; Kentaro Minagawa; Kenji Yoshida; Ryohei Sasaki; Shunji Nakayama; Hiroshi Yokozaki; Emmy Yanagita; Tomoo Itoh; Yoshitake Hayashi; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

Review 2.  How I treat autoimmune lymphoproliferative syndrome.

Authors:  V Koneti Rao; João Bosco Oliveira
Journal:  Blood       Date:  2011-09-01       Impact factor: 22.113

3.  Is Rosai-Dorfman disease a reactve process? Detection of a MAP2K1 L115V mutation in a case of Rosai-Dorfman disease.

Authors:  Matthias S Matter; Michel Bihl; Darius Juskevicius; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2017-06-09       Impact factor: 4.064

4.  Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.

Authors:  Vignesh Shanmugam; Elizabeth Margolskee; Michael Kluk; Tamara Giorgadze; Attilio Orazi
Journal:  Head Neck Pathol       Date:  2016-02-27

5.  Bone marrow findings in autoimmune lymphoproliferative syndrome with germline FAS mutation.

Authors:  Yi Xie; Stefania Pittaluga; Susan Price; Mark Raffeld; Jamie Hahn; Elaine S Jaffe; V Koneti Rao; Irina Maric
Journal:  Haematologica       Date:  2016-10-20       Impact factor: 9.941

6.  Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.

Authors:  Susan Price; Pamela A Shaw; Amy Seitz; Gyan Joshi; Joie Davis; Julie E Niemela; Katie Perkins; Ronald L Hornung; Les Folio; Philip S Rosenberg; Jennifer M Puck; Amy P Hsu; Bernice Lo; Stefania Pittaluga; Elaine S Jaffe; Thomas A Fleisher; V Koneti Rao; Michael J Lenardo
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

Review 7.  Autoimmune lymphoproliferative syndrome: an update and review of the literature.

Authors:  Shaili Shah; Eveline Wu; V Koneti Rao; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2014-09       Impact factor: 4.806

8.  Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 5.

Authors:  Dita Gratzinger; Elaine S Jaffe; Amy Chadburn; John K C Chan; Daphne de Jong; John R Goodlad; Jonathan Said; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

9.  NRAS Mutations May Be Involved in the Pathogenesis of Cutaneous Rosai Dorfman Disease: A Pilot Study.

Authors:  Kuan-Jou Wu; Shu-Hao Li; Jia-Bin Liao; Chien-Chun Chiou; Chieh-Shan Wu; Chien-Chin Chen
Journal:  Biology (Basel)       Date:  2021-05-02

10.  Case Report: Eighteen Month Relapse- Free Survival Following Radical Multidisciplinary Oncological Treatment in a 68-Year-Old Male Patient With Histiocytic Sarcoma.

Authors:  Stefan Wehrmann; Hagen Rudolph; Dominikus Ernst; Timo Siepmann; Dorothea Kaltofen; Mathias Hänel; Lutz Mirow
Journal:  Front Oncol       Date:  2021-06-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.